You can buy or sell RUBY and other stocks, options, ETFs, and crypto commission-free!
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA. Read More The listed name for RUBY is Rubius Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 12, Pre-Market